Mostrando 4 resultados de: 4
Filtros aplicados
Subtipo de publicación
Article(4)
Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof-of-Principle Issues from a Randomized Controlled Study
ArticleAbstract: Background: Several pieces of evidence have shown the neurotrophic effect of erythropoietin (EPO) anPalabras claves:Clinical trial, erythropoietin, human-recombinant erythropoietin, spinocerebellar ataxia type 2Autores:Almaguer Gotay D., Amaro-González D., Aymed-García J., Batista-Nuñez M., Canales-Ochoa N., Carmen Elena Viada, Columbié Ximelis J., Crombet-Ramos T., Estupiñán Rodriguez A., García-García I., García-Rodriguez J.C., Hernández Casaña P., Jiménez-Rodríguez D., Labrada Aguilera P.E., Medrano Montero J., Ortega-Sanchez R., Padrón-Estupiñan M.d.C., Peña Acosta A., Rodríguez-Labrada R., Rodriguez-Obaya T., Santos-Morales O., Silva Ricardo Y., Torres Vega R., Tribin Rivero K., Valenzuela-Silva C.M., Valle Cabrera R., Vazquez-Mojena Y., Velazquez-Perez L.Fuentes:scopusUse of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19
ArticleAbstract: Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a recent outbreaPalabras claves:Autores:Caballero A., Calderón N.A., Cepeda M., Diáz Y., Estevez D., Hidalgo C.J., La O Y., Leon K., Lorenzo G., Luaces P.L.o., Martín Y., Mazorra Z., Oyarzábal J.P.A., Pérez Y., Ramos-Suzarte M., Saavedra Hernández D., Santiago W., Tania Crombet, Valenzuela-Silva C.M., Viñet O.Fuentes:scopusSafety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults
ArticleAbstract: Background: SOBERANA 02 has been evaluated in phase I and IIa studies comparing homologous versus hePalabras claves:Conjugate vaccine, covid-19, heterologous schedule, phase IIb clinical trial, recombinant RBD, Translation to patientsAutores:Acevedo-Martínez Y., Acosta-Martinez M.A., Alfaro-Guzmán A., Amoroto M., Arteaga-García A., Ávila-Cabreja J.A., Baro-Roman G., Bergado-Baez G., Biglari A., Boggiano-Ayo T., Brito-Pascual I., Cardoso-SanJorge F., Chen G.W., Climent-Ruiz Y., Coviella-Artime J.M., Cruz-Sui O., Cubas-Curbelo M., Díaz-Hernández M., Domínguez-Pentón Y.R., Doroud D., Dubed-Echevarría M., Enriquez-Puertas J., Espi-Ávila J., Espino-Rojas N.T., Estoque-Cabrera S., Fernández-Castillo S., Fontanies-Fernández M., Galano-Frutos E., Garcés-Hechavarría A., García-Carmenate M., García-López E., García-Montero M., García-Rivera D., García-Vega Y., Garrido-Arteaga R., Gómez-Maceo Y., González-Mugica R., Guillén-Obregón B., Hernández-Garcia T., Lora-García J., Martínez-Bedoya D., Martínez-Pérez M., Martínez-Rivera R., Medina-Nápoles M., Medinas-Santos G.M., Mendoza-Hernández I., Misladys Rodríguez Ortega, Morales-Ruano S., Morffi-Cinta I., Muñoz Y., Noa-Romero E., Ojito-Magaz E., Ontivero-Pino I., Orosa-Vázquez I., Palenzuela-Diaz A., Paredes-Moreno B., Pérez-Guevara M.T., Perez-Perez A., Pérez-Rodríguez S., Pi-Estopiñán F., Quintero-Moreno L., Ramírez-Gonzalez U., Reyes-Matienzo R., Rivera D.G., Rodríguez-Castillo P.G., Rodriguez-González M., Rodríguez-Noda L., Sanchez-Ramirez B., Santana-Mederos D., Santos-Vega B.L., Sarda-Rodriguez I.L., Toledo-Romani M.E., Valdes-Balbín Y., Valenzuela-Silva C.M., Valera-Fernández R., Verdecia-Sánchez L., Verez-Bencomo V., Zulueta-Pérez L.Fuentes:scopusSafety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies
ArticleAbstract: Background: Cervical cancer is now considered the second leading cause of death among women worldwidPalabras claves:Autores:Acevedo B.E., Alonso D.F., Baladron I., Castillo D., Díaz A., Gómez R., González C.A., Herrera L., López-Saura P.A., Perea-Rodríguez S.E., Santana A., Sigman H., Solares A.M., Thelvia I. Ramos Gómez, Valenzuela-Silva C.M.Fuentes:googlescopus